Clinical Trial Update: Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study assessing safety, pharmacokinetics, and efficacy of oral CC-223 in advanced solid tumors, non-Hodgkin lymphoma, or multiple myeloma; trial compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Multiple Myeloma

Drugs mentioned

• CC-223

Snippet

Sponsor: Celgene | Conditions: Multiple Myeloma, Diffuse Large B-Cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-11-15